[go: up one dir, main page]

CA2397253A1 - Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives - Google Patents

Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives Download PDF

Info

Publication number
CA2397253A1
CA2397253A1 CA002397253A CA2397253A CA2397253A1 CA 2397253 A1 CA2397253 A1 CA 2397253A1 CA 002397253 A CA002397253 A CA 002397253A CA 2397253 A CA2397253 A CA 2397253A CA 2397253 A1 CA2397253 A1 CA 2397253A1
Authority
CA
Canada
Prior art keywords
6alkyl
hydrogen
6alkyloxy
formula
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002397253A
Other languages
French (fr)
Inventor
Mary Ellen Margaret Rybak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2397253A1 publication Critical patent/CA2397253A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is concerned with combinations of a farnesyl transferase inhibitor and an anthracycline derivative for inhibiting the growth of tumor cells and useful in the treatment of cancer.

Description

FARNESYL PROTEIN TRANSFERASE IIVIBBITOR COMBINATIONS
WITH ANTI-TUMOR ANTHRACYCLINE DERIVATIVES
The present invention is concerned with combinations of a farnesyl transferase inhibitor and an anti-tumor anthracycline derivative for inhibiting the growth of tumor cells. and useful in the treatment of cancer.
Oncogenes frequently encode protein components of signal transduction pathways 1o which lead to stimulation of cell growth and mitogenesis. Oncogene expression in cultured cells leads to cellular transformation, characterized by the ability of cells to grow in soft agar and the growth of cells as dense foci lacking the contact inhibition exhibited by non-transformed cells. Mutation and/or overexpression of certain oncogenes is frequently associated with human cancer. A particular group of 15 oncogenes is known as ras which have been identified in mammals, birds, insects, mollusks, plants, fungi and yeasts. The family of mammalian ras oncogenes consists of three major members ("isoforms") : H-ras, K-ras and N-ras oncogenes. These ras oncogenes code for highly related proteins generically known as p21 ras, pnce attached to plasma membranes, the mutant or oncogenic forms of p21 ras will provide a signal 2o for the transformation and uncontrolled growth of malignant tumor cells. To acquire this transforming potential, the precursor of the p2lras oncoprotein must undergo an enzymatically catalyzed farnesylation of the cysteine residue located in a carboxyl-terminal tetrapeptide. Therefore, inhibitors of the enzyme that catalyzes this modification, farnesyl protein transferase, will prevent the membrane attachment of 25 p2lras and block the aberrant growth of ras-transformed tumors. Hence, it is generally accepted in the art that farnesyl transferase inhibitors can be very useful as anticancer agents for tumors in which ras contributes to transformation.
Since mutated, oncogenic forms of ras are frequently found in many human cancers, 3o most notably in more than 50 % of colon and pancreatic carcinomas (Kohl et al., Science, vol 260, 1834 - 1837, 1993), it has been suggested that farnesyl tranferase inhibitors can be very useful against these types of cancer. Following further investigations, it has been found that a farnesyl transferase inhibitor is capable of demonstrating antiproliferative effects in vitro and antitumor effects in vivo in a variety 35 of human tumor cell lines with and without ras gene mutations WO-97/21701 describes the preparation, formulation and pharmaceutical properties of farnesyl protein transferase inhibiting (imidazoly-5-yl)methyl-2-quinolinone derivatives of formulas (I), (II) and (III), as well as intermediates of formula (II) and (III) that are metabolized in vivo to the compounds of formula (I). The compounds of formulas (I), (II) and (III) are represented by R
Rt7 (I) (B) ~~ iR5 N+' O-(III) the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond;
X is oxygen or sulfur;
R1 is hydrogen, CI-l2alkyl, ArI, Ar2C1_6alkyl, quinolinylCl-(alkyl, pyridylCl_6alkyl, hydroxyCl_6alkyl, C1_6alkyloxyCl-(alkyl, mono- or di(C1_6alkyl)aminoCl_6alkyl, aminoCl_6alkyl, or a radical of formula -Alkl-C(=O)-R9, -AIkI-S(O)-R9 or -AIkI-S(O)2-R9, wherein AIkI is C1_6alkanediyl, R9 is hydroxy, C1_6alkyl, C1_6alkyloxy, amino, Cl_galkylamino or C1_galkylamino substituted with C1_6alkyloxycarbonyl;
R2, R3 and RI6 each independently are hydrogen, hydroxy, halo, cyano, C1_6alkyl, C1_6alkyloxy, hydroxyCl_6alkyloxy, C1_6alkyloxyCl-6alkyloxy, aminoCl_6alkyl-oxy, mono- or di(C1_6alkyl)aminoCl_6alkyloxy, ArI, Ar2C1_6alkyl, Ar2oxy, ~'2C1-6alkyloxy, hydroxycarbonyl, C1_6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2_6alkenyl, 4,4-dimethyloxazolyl; or when on adjacent positions R2 and R3 taken together may form a bivalent radical of formula -O-CH2-O- (a-1 ), -O-CH2-CH2-O- (a-2), -O-CH=CH- (a-3), -O-CH2-CH2- (a-4), -O-CH2-CH2-CH2- (a-5), or -CH=CH-CH=CH- (a-6);
R4 and RS each independently are hydrogen, halo, Arl, C1-(alkyl, hydroxyCl_6alkyl, C1_6alkyloxyCl_6alkyl, C1_6alkyloxy, C1_6alkylthio, amino, hydroxycarbonyl, C1_6alkyloxycarbonyl, C1_6a1ky1S(O)C1_6alkyl or C1_6a1ky1S(O)2C1_6alkyl;
to R6 and R~ each independently are hydrogen, halo, cyano, C 1 _6alkyl, C 1 _6alkyloxy, Ar2oxy, trihalomethyl, C1_6alkylthio, di(C1_6alkyl)amino, or when on adjacent positions R6 and R~ taken together may form a bivalent radical of formula -O-CH2-O- (c-1 ), or -CH=CH-CH=CH- (c-2);
Rg is hydrogen, C1_6alkyl, cyano, hydroxycarbonyl, C1_6alkyloxycarbonyl, C 1 _6alkylcarbonylC 1 _6alkyl, cyanoC 1 _6alkyl, C 1 _6alkyloxycarbonylC 1 _(alkyl, carboxyCl_6alkyl, hydroxyCl_6alkyl, aminoCl_6alkyl, mono- or di(C1_6alkyl)-aminoCl_6alkyl, imidazolyl, haloCl_6alkyl, C1_6alkyloxyCl-6alkyl, aminocarbonylCl_6alkyl, or a radical of formula -O-R 10 (b-1 ), -S-R 10 (b-2), -N-R 11 R 12 (b-3 ), wherein R10 is hydrogen, C1_6alkyl, C1_6alkylcarbonyl, Arl, Ar2C1_6alkyl, C1_6alkyloxycarbonylCl_6alkyl, or a radical or formula -Alk2-OR13 or -Alk2-NR14R15;
R11 is hydrogen, C1_l2alkyl, Arl or Ar2C1_6alkyl;
R 12 is hydrogen, C 1 _6alkyl, C 1 _ l6alkylcarbonyl, C 1 _6alkyloxycarbonyl, C1_6alkylaminocarbonyl, Arl, Ar2C1_6alkyl, C1_6alkylcarbonyl-3o C1_6alkyl, a natural amino acid, Arlcarbonyl, Ar2C1_6alkylcarbonyl, aminocarbonylcarbonyl, C1_6alkyloxyCl_6alkylcarbonyl, hydroxy, C1_6alkyloxy, aminocarbonyl, di(C1_6alkyl)aminoCl_6alkylcarbonyl, amino, C1_6alkylamino, C1_6alkylcarbonylamino, or a radical or formula -Alk2-OR13 or -Alk2-NR14R15;
wherein Alk2 is C1-(alkanediyl;
R13 is hydrogen, C1_6alkyl, C1_6alkylcarbonyl, hydroxy-C1_6alkyl, Arl or Ar2C1_6alkyl;
R 14 is hydrogen, C 1 _6alkyl, Arl or Ar2C 1 _6alkyl;
R I S is hydrogen, C 1 _6alkyl, C I _6alkylcarbonyl, ArI or Ar2C I _6alkyl;
R I7 is hydrogen, halo, cyano, C 1 _6alkyl, C l _6alkyloxycarbonyl, ArI ;
R I g is hydrogen, C I _6alkyl, C I _6alkyloxy or halo;
RI9 is hydrogen or Cl_6alkyl;
ArI is phenyl or phenyl substituted with C1_6alkyl, hydroxy, amino, Cl_6alkyloxy or halo; and Ar2 is phenyl or phenyl substituted with C1_6alkyl, hydroxy, amino, C1_6alkyloxy or halo.
to WO-97/16443 concerns the preparation, formulation and pharmaceutical properties of farnesyl protein transferase inhibiting compounds of formula (IV), as well as intermediates of formula (V) and (VI) that are metabolized in vivo to the compounds of formula (IV). The compounds of formulas (IV), (V) and (VI) are represented by ~\~~R t 6 R4 R;~/R 16 R4 ~~ iR5 RZ r ' ~~ ~ RS
/ NJ /
Rtw ~ /~ /~ /~ Rt7 R8 ~~ i R6 ~ ~~ ~ R8 ~~ i R6 ~w v Rt9 Rts R~ Rt9 Rt8 Rt (IV) (V) R
(VI) the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond;
X is oxygen or sulfur;
R1 is hydrogen, CI-l2alkyl, ArI, Ar2Cl_6alkyl, quinolinylCl_6alkyl, pyridyl-C1_6alkyl, hydroxyCl_6alkyl, Cl_6alkyloxyCl_6alkyl, mono- or di(C1_6alkyl)-1~t9 __ O-aminoCl_6alkyl, aminoCl_6alkyl, or a radical of formula -Alkl-C(=O)-R9, -Alkl-S(O)-R9 or -AIkI-S(O)2-R9, wherein Alkl is Cl_6alkanediyl, R9 is hydroxy, C 1 _6alkyl, C 1 _6alkyloxy, amino, C 1 _galkylamino or C1_galkylamino substituted with C1_6alkyloxycarbonyl;
R2 and R3 each independently are hydrogen, hydroxy, halo, cyano, C1_6alkyl, Cl_6alkyloxy, hydroxyCl_6alkyloxy, C1_6alkyloxyCl_6alkyloxy, amino-C1_6alkyloxy, mono- or di(C1_6alkyl)aminoCl_6alkyloxy, Arl, Ar2C1_6alkyl, Ar2oxy, Ar2C1_6alkyloxy, hydroxycarbonyl, C1_6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2_6alkenyl; or when on adjacent positions R2 and R3 taken together may form a bivalent radical of formula -O-CH2-O- (a-1 ), -O-CHZ-CH2-O- (a-2), -O-CH=CH- (a-3), -O-CH2-CH2- (a-4), -O-CHZ-CH2-CHZ- (a-5), or -CH=CH-CH=CH- (a-6);
R4 and RS each independently are hydrogen, Ar', C1_6alkyl, C1_6alkyloxyC,_balkyl, 2o C1_6alkyloxy, C1_6alkylthio, amino, hydroxycarbonyl, C1_6alkyloxycarbonyl, C1_6alkylS(O)C1_6alkyl or C1_6alkylS(O)ZC,_balkyl;
R6 and R~ each independently are hydrogen, halo, cyano, Cl_6alkyl, C1_6alkyloxy or Ar2oxy;
R8 is hydrogen, C1_6alkyl, cyano, hydroxycarbonyl, C1_6alkyloxycarbonyl, C1_6alkyl-carbonylCl_6alkyl, cyanoCl_6alkyl, C1_6alkyloxycarbonylCl_6alkyl, hydroxy-carbonylCl_6alkyl, hydroxyCl_6alkyl, aminoCl_6alkyl, mono- or di(C1_6alkyl)-aminoCl_6alkyl, haloCl_6alkyl, C1_6alkyloxyCl_6alkyl, aminocarbonylCl-(alkyl, Arl , Ar2C 1 _6alkyloxyC 1 _6alkyl, C 1 _6alkylthioC 1 _6alkyl;
R 10 is hydrogen, C I _6alkyl, C I _6alkyloxy or halo;
3o R11 is hydrogen or C1_6alkyl;
ArI is phenyl or phenyl substituted with C 1 _6alkyl, hydroxy, amino, Cl _(alkyloxy or halo;
Ar2 is phenyl or phenyl substituted with C 1 _6alkyl, hydroxy, amino, CI
_6alkyloxy or halo.
WO-98/40383 concerns the preparation, formulation and pharmaceutical properties of farnesyl protein transferase inhibiting compounds of formula (VII) ~ 4 R

(VII) the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond;
X is oxygen or sulfur;

-A- is a bivalent radical of formula -CH=CH- (a-1), -CH2-S- (a-6), to -CH2-CH2- (a-2), -CH2-CH2-S- (a-7), -CH2-CH2-CH2- (a-3), -CH=N- (a-8), -CH2-O- (a-4), -N=N- (a-9), or -CH2-CH2-O- (a-5), -CO-NH- (a-10);

wherein optionally one hydrogen atom may be replaced by CI_4alkyl or ArI;
R1 and R2 each independently are hydrogen, hydroxy, halo, cyano, Cl_6alkyl, trihalomethyl, trihalomethoxy, C2_6alkenyl, CI_6alkyloxy, hydroxyCl_6alkyloxy, C1_6alkyloxyCl_6alkyloxy, Cl_6alkyloxycarbonyl, aminoCl_6alkyloxy, mono- or di(C1_6alkyl)aminoCl_6alkyloxy, Ar2, Ar2-C1_6alkyl, Ar2-oxy, Ar2-CI_6alkyloxy; or when on adjacent positions R1 and R2 taken together may 2o form a bivalent radical of formula -O-CH2-O- (b-1 ), -O-CH2-CH2-O- (b-2), -O-CH=CH- (b-3), -O-CH2-CH2- (b-4), -O-CH2-CH2-CH2- (b-5), or -CH=CH-CH=CH- (b-6);
R3 and R4 each independently are hydrogen, halo, cyano, C 1 _6alkyl, C 1 _6alkyloxy, Ar3-oxy, CI_6alkylthio, di(C1_6alkyl)amino, trihalomethyl, trihalomethoxy, or when on adjacent positions R3 and R4 taken together may form a bivalent radical of formula -O-CH2-O- (c-1), -O-CH2-CH2-O- (c-2), or -CH=CH-CH=CH- (c-3);
RS is a radical of formula - ~ ~ ~d_1), ~J R~3 ~d_2), i3 Rya wherein R13 is hydrogen, halo, Ar4, C1_6alkyl, hydroxyCl_6alkyl, C1_6alkyloxy-C1-6alkyl, C1_6alkyloxy, Cl_6alkylthio, amino, Cl_6alkyloxy-carbonyl, C1_6alkylS(O)C1_6alkyl or C1_6alkylS(O)2C1_6alkyl;
Rl4is hydrogen, Cl_6alkyl or di(Cl-4alkyl)aminosulfonyl;
R6 is hydrogen, hydroxy, halo, C1_6alkyl, cyano, haloCl_6alkyl, hydroxyCl_6alkyl, cyanoC 1 _6alkyl, aminoC 1 _6alkyl, C 1 _6alkyloxyC 1 _6alkyl, to Cl_6alkylthioCl_6alkyl, aminocarbonylCl_6alkyl, C1_6alkyloxycarbonylCl_6alkyl, C1_6alkylcarbonyl-C1_6alkyl, Cl_6alkyloxycarbonyl, mono- or di(C1_6alkyl)aminoCl_6alkyl, ArS, Ar5-C1_6alkyloxyCl_6alkyl; or a radical of formula _0_R7 (e-1), ~5 -S-R~ (e-2), -N_R8R9 (e-3), wherein R~ is hydrogen, C 1 _6alkyl, C 1 _6alkylcarbonyl, Ar6, Ar6-C 1 _6alkyl, C1_6alkyloxycarbonylCl_6alkyl, or a radical of formula -Alk-OR10 or -Alk-NR 11 R 12;
2o R8 is hydrogen, C1_6alkyl, Ark or Ark-C1_6alkyl;
R9 is hydrogen, C1_6alkyl, C1_6alkylcarbonyl, C1_6alkyloxycarbonyl, C 1_6alkylaminocarbonyl, Arg, Arg-C 1 _6alkyl, C 1 _6alkylcarbonyl-C 1_6alkyl, Arg-carbonyl, Arg-C 1 _6alkylcarbonyl, aminocarbonyl-carbonyl, C1_(alkyloxyCl_(alkylcarbonyl, hydroxy, C1_(alkyloxy, 25 aminocarbonyl, di(C 1 _6alkyl)aminoC 1-(alkylcarbonyl, amino, C1_6alkylamino, C1_6alkylcarbonylamino, or a radical or formula -Alk-OR 1 ~ or -Alk-NR 11 R 12;
wherein Alk is C1_6alkanediyl;
R l ~ is hydrogen, C 1 _6alkyl, C 1 _6alkylcarbonyl, hydroxyC 1 _6alkyl, 3o Ar9 or Ar9-C1_6alkyl;
R11 is hydrogen, C1_6alkyl, C1_6alkylcarbonyl, Arl~ or Ar l ~-C 1-( alkyl;
R12 is hydrogen, C1_6alkyl, Aril or Aril-C1-6alkyl; and Arl to Arl l are each independently selected from phenyl; or phenyl substituted 35 with halo, C 1 _6alkyl, C 1_6alkyloxy or trifluoromethyl.

_g_ WO-98/49157 concerns the preparation, formulation and pharmaceutical properties of farnesyl protein transferase inhibiting compounds of formula (VIII) R
,s (VIII) the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond;
X is oxygen or sulfur;
R1 and R2 each independently are hydrogen, hydroxy, halo, cyano, C1_6alkyl, l0 trihalomethyl, trihalomethoxy, C2_6alkenyl, C1_6alkyloxy, hydroxyCl_6alkyloxy, C1_6alkyloxyCl_6alkyloxy, C1_6alkyloxycarbonyl, aminoCl_6alkyloxy, mono- or di(C1_6alkyl)aminoCl_6alkyloxy, Arl, ArlC1_6alkyl, Arloxy or Arl C 1 _6alkyloxy;
R3 and R4 each independently are hydrogen, halo, cyano, C 1 _6alkyl, C 1 _6alkyloxy, Arloxy, C1_6alkylthio, di(C1_6alkyl)amino, trihalomethyl or trihalomethoxy;
RS is hydrogen, halo, C1_6alkyl, cyano, haloCl_6alkyl, hydroxyCl_6alkyl, cyanoCl_6alkyl, aminoCl_6alkyl, C1_6alkyloxyCl_6alkyl, C1_6alkylthioCl_6alkyl, aminocarbonylCl_6alkyl, C1_6alkyloxycarbonylCl_6alkyl, C1_6alkylcarbonyl-C1_6alkyl, 2o C1_6alkyloxycarbonyl, mono- or di(C1_6alkyl)aminoCl_6alkyl, Arl, ArlC1_6alkyloxyCl_6alkyl; or a radical of formula -O-R10 (a-1), -S-R10 (a-2), -N-R11R12 (a-3), wherein R1~ is hydrogen, C1_6alkyl, C1_6alkylcarbonyl, Arl, ArlC1_6alkyl, C1_6alkyloxycarbonylCl_6alkyl, or a radical of formula -Alk-OR13 or -Alk-NR 14R 15;
R11 is hydrogen, C1_6alkyl, Arl or ArlC1_6alkyl;
R12 is hydrogen, C1_6alkyl, C1_6alkylcarbonyl, C1_6alkyloxycarbonyl, 3o C1_6alkylaminocarbonyl, Arl, ArlC1_6alkyl, C1_6alkylcarbonyl-C1_6alkyl, Arlcarbonyl, ArlC1_6alkylcarbonyl, aminocarbonyl-R° Ry carbonyl, C 1 _6alkyloxyC 1 _6alkylcarbonyl, hydroxy, C 1 _6alkyloxy, aminocarbonyl, di(Cl_6alkyl)aminoCl_6alkylcarbonyl, amino, Cl_6alkylamino, Cl_6alkylcarbonylamino, or a radical or formula -Alk-OR13 or -Alk-NR14R15~
wherein Alk is Cl_6alkanediyl;
R 13 is hydrogen, C 1 _6alkyl, C 1 _6alkylcarbonyl, hydroxy-C1_6alkyl, Arl or ArlCl_6alkyl;
R14 is hydrogen, C1_6alkyl, Arl or ArlCl_6alkyl;
R 15 is hydrogen, C 1 _6alkyl, C 1 _6alkylcarbonyl, Arl or l0 ArlCl_6alkyl;
R6 is a radical of formula - ~ ~ ~b_1) ~J Ri6 ~b_2), N
i6 Rm wherein Rl6is hydrogen, halo, Arl, C1_6alkyl, hydroxyCl-(alkyl, Cl_6alkyloxy-C 1 _6alkyl, C 1 _6alkyloxy, C 1 _6alkylthio, amino, Cl_6alkyloxycarbonyl, C1_6alkylthioCl_6alkyl, Cl_6alkylS(O)Cl_6alkyl or C1_6alkylS(O)2C1_6alkyl;
Rl~is hydrogen, Cl_6alkyl or di(Cl_4alkyl)aminosulfonyl;
R~ is hydrogen or Cl_6alkyl provided that the dotted line does not represent a bond;
R8 is hydrogen, C1_6alkyl or Ar2CH2 or HetlCH2;
2o R9 is hydrogen, C1_6alkyl , Cl_6alkyloxy or halo; or R8 and R9 taken together to form a bivalent radical of formula -CH=CH- (c-1), -CH2-CH2- (c-2), -CH2-CH2-CH2- (c-3), -CH2-O- (c-4), or -CH2-CH2-O- (c-5);
Arl is phenyl; or phenyl substituted with 1 or 2 substituents each independently selected from halo, Cl_6alkyl, Cl_6alkyloxy or trifluoromethyl;
Ar2 is phenyl; or phenyl substituted with 1 or 2 substituents each independently 3o selected from halo, Cl_6alkyl, Cl_6alkyloxy or trifluoromethyl; and Hetl is pyridinyl; pyridinyl substituted with 1 or 2 substituents each independently selected from halo, C1_6alkyl, Cl_6alkyloxy or trifluoromethyl.
WO-00/39082 concerns the preparation, formulation and pharmaceutical properties of farnesyl protein transferase inhibiting compounds of formula (IX) (Rl)~ (RZ)s / /

(IX) ~R
.v.J
X N (Rs)i or the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein =X1-XZ-X3- is a trivalent radical of formula =N-CR6=CR'- (x-1), =CR6-CR'=CR8- (x-6), =N-N=CR6- (x-2), =CR6-N=CR'- (x-7), =N-NH-C(=O)- (x-3), =CR6-NH-C(=O)- (x-8), or =N-N=N- (x-4), =CR6-N=N- (x-9);

l0 =N-CR6=N- (x-5), wherein each R6, R' and g are independently hydrogen, R C,_4alkyl, hydroxy, C~_4alkyloxy, ary loxy, alkyloxycarbonyl, hydroxyCl_4alkyl, Cl~ C1_4alkyloxy-C1_4alkyl, mono- or di(Cl~alkyl)aminoCl~alkyl, cyano, amino, thio, C,_4alkyl-thio, arylthio or aryl;
>Y1-Y2- is a trivalent radical of formula >CH-CHR9- (y-1), >C=N- (y-2), >CH-NR9- (y-3),or >C=CR9- (y-4);
wherein each R9 independently is hydrogen, halo, halocarbonyl, aminocarbonyl, hydroxyCl_4alkyl, cyano, carboxyl, C1_4alkyl, C1_4alkyloxy, C1_4alkyloxyCl~alkyl, Cl~alkyloxycarbonyl, mono- or di(C~_4alkyl)amino, mono- or di(C~_4alkyl)aminoCl~alkyl, aryl;
r and s are each independently 0, 1, 2, 3, 4 or 5;
tis0, l,2or3;
each R1 and R2 are independently hydroxy, halo, cyano, C1_6alkyl, trihalomethyl, trihalomethoxy, CZ_6alkenyl, C1_6alkyloxy, hydroxyC,_6alkyloxy, C1_6alkylthio, CI_6alkyloxyCl_6alkyloxy, C1_6alkyloxycarbonyl, aminoCl_6alkyloxy, mono- or di(C1_6alkyl)amino, mono- or di(C,_6alkyl)aminoCl_6alkyloxy, aryl, arylC1_6alkyl, 3o aryloxy or arylC1_6alkyloxy, hydroxycarbonyl, Cl_6alkyloxycarbonyl, aminocarbonyl, aminoCl~alkyl, mono- or di(C1_6alkyl)aminocarbonyl, mono- or di(C,_6alkyl)aminoCl_6alkyl; or two R' or Rz substituents adjacent to one another on the phenyl ring may independently form together a bivalent radical of formula _O_CHz_O- (a-1), -O-CHz-CHz-O- (a-2), -O=CH=CH- (a-3), -O-CHz-CHz- (a-4), -O-CHz-CHz- CHz- (a-5), or -CH=CH-CH=CH- (a-6);
R3 is hydrogen, halo, C1_6alkyl, cyano, haloCl_balkyl, hydroxyCl_6alkyl, to cyanoCl_6alkyl, aminoCl_6alkyl, C1_6alkyloxyCl_6alkyl, C,_6alkylthioC~_6alkyl, aminocarbonylC,_6alkyl, hydroxycarbonyl, hydroxycarbonylCl_6alkyl, C1_6alkyloxycarbonylCl_6alkyl, C1_6alkylcarbonylCl_6alkyl, C~_6alkyloxycarbonyl, aryl, arylCl_6alkyloxyCl_6alkyl, mono- or di(C1_6alkyl)aminoCl_6alkyl;
or a radical of formula -O-R'° (b-1 ), -S-R'° (b-2), -~uR~z (b-3)~
wherein R'° is hydrogen, C,_6alkyl, C1_6alkylcarbonyl, aryl, arylC1_6alkyl, C~_6alkyloxycarbonylCl_6alkyl, or a radical of formula -Alk-OR'3 or -Alk-NR'4R's;
R" is hydrogen, C1_6alkyl, aryl or arylCl_6alkyl;
R'z is hydrogen, C1_6alkyl, aryl, hydroxy, amino, C1_6alkyloxy, C~_6alkylcarbonylCl_6alkyl, arylC1_6alkyl, C1_6alkylcarbonylamino, mono-or di(C1_6alkyl)amino, C1_6alkylcarbonyl, aminocarbonyl, arylcarbonyl, haloCl_6alkylcarbonyl, arylCl_6alkylcarbonyl, C~_6alkyloxycarbonyl, C~_6alkyloxyCl_6alkylcarbonyl, mono- or di(C1_6alkyl)aminocarbonyl wherein the alkyl moiety may optionally be substituted by one or more substituents independently selected from aryl or C1_3alkyloxycarbonyl, aminocarbonylcarbonyl, mono- or di(C1_6alkyl)aminoCl_6alkylcarbonyl, 3o or a radical or formula -Alk-OR'3 or -Alk-NR'4R's;
wherein Alk is C1_6alkanediyl;
R'3 is hydrogen, C1_6alkyl, C1_6alkylcarbonyl, hydroxyCi_6alkyl, aryl or arylCl_6alkyl;
R'4 is hydrogen, CI_6alkyl, aryl or arylC1_6alkyl;
R's is hydrogen, C1_6alkyl, C1_balkylcarbonyl, aryl or arylC~_6alkyl;
R4 is a radical of formula -N~ J O-1), ~J R16 (c_2), N

R
wherein R16 is hydrogen, halo, aryl, C,_balkyl, hydroxyC,_6alkyl, C,_6alkyloxyCl_~alkyl, C1_~alkyloxy, C,_6alkylthio, amino, mono- or di(C1_4alkyl)amino, hydroxycarbonyl, C1_6alkyloxycarbonyl, C1_6alkylthioC,_6alkyl, C1_6alkylS(O)C1_6alkyl or C1_6alkylS(O)ZCl_6alkyl;
R16 may also be bound to one of the nitrogen atoms in the imidazole ring of formula (c-1) or (c-2), in which case the meaning of R16 when bound to the nitrogen is limited to hydrogen, aryl, C1_6alkyl, hydroxyCl_6alkyl, C1_6alkyloxyCl_6alkyl, C1_balkyloxycarbonyl, C1_6alkylS(O)C,_6alkyl or l0 C1_6alkylS(O)ZC1_6alkyl;
R" is hydrogen, C1_6alkyl, C1_6alkyloxyCl_6alkyl, arylCl_6alkyl, trifluoromethyl or di(C1_4alkyl)aminosulfonyl;
RS is C1_6alkyl , C,_6alkyloxy or halo;
aryl is phenyl, naphthalenyl or phenyl substituted with 1 or more substituents each 15 independently selected from halo, C1_6alkyl, C,_6alkyloxy or trifluoromethyl.
Anthracycline derivatives are important anti-tumor agents and comprise antibiotics obtained from the fungus Strep. peuticus var. caesius and their derivatives, characterised by having a tetracycline ring structure with an unusual sugar, 2o daunosamine, attached by a glycosidic linkage. Among these compounds, the most widely used include daunorubicin, which has the chemical name 7-(3-amino-2,3,6-trideoxy-L-lyxohexosyloxy)-9-acetyl-7,8,9,10-tetrahydro-6,9,11-trihydroxy-4-methoxy-5,12-naphthacenequinone, doxorubicin, which has the chemical name 10-[(3-amino-2,3,6-trideoxy-alphaL-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-25 8-(hydroxylacetyl)-1-methoxy-5,12-naphthacenedione, and idarubicin, which has the chemical name 9-acetyl-7-[(3-amino-2,3,6-trideoxy-alphaL-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione. Daunorubicin and idarubicin have been used primarily for the treatment of acute leukaemias whereas doxorubicin displays broader activity against human neoplasms, including a variety of 3o solid tumors particularly breast cancer. However, anthracycline derivatives generally display a serious cardiomyopathy at higher doses, which limits the doses at which these compounds can be administered.
There is therefore a need to increase the inhibitory efficacy of anti-tumor anthracycline 35 derivatives against tumor growth and also to provide a means for the use of lower dosages of anti-tumor anthracycline derivatives to reduce the potential of adverse toxic side effects to the patient.
It is an object of the invention to provide a therapeutic combination of an anti-tumor anthracycline derivative and a farnesyl transferase inhibitor of the type described above which has an advantageous inhibitory effect against tumor cell growth, in comparison with the respective effects shown by the individual components of the combination.
According to the invention therefore we provide a combination of an anti-tumor anthracycline derivative and a farnesyl transferase inhibitor of formula (I), (>I), (III), (IV), to (V), (VI), (VII), (VIII) or (IX) above, in particular a compound of formula (I), (II) or (III):
R~~~R~6 R4 R3~ Ri6 R4 l O ~~=,R r\ ,.~ ~=~=,R
RZ ~ HN ~~ 5 RZ l ~ HN. ~~
Ri7W /~/f~/~ Ro i R
R8 ~~~ R6 ~ N~~s~~ R$
R~9 Ris R~ Ri9 Ris cn an cBn the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond;
X is oxygen or sulfur;
Rl is hydrogen, Cl_l2alkyl, ArI, Ar2Cl_6alkyl, quinolinylCl_6alkyl, pyridyl-C1_6alkyl, hydroxyCl_6alkyl, C1_6alkyloxyCl_6alkyl, mono- or 2o di(C1_6alkyl)aminoCl_6alkyl, aminoCl_6alkyl, or a radical of formula -AIkI-C(=O)-R9, -AIkI-S(O)-R9 or -AIkI-S(O)2-R9, wherein AIkI is C1_6alkanediyl, R9 is hydroxy, C1_6alkyl, Cl_6alkyloxy, amino, CI_galkylamino or C1_galkylamino substituted with C1_6alkyloxycarbonyl;
R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1_6alkyl, C 1 _6alkyloxy, hydroxyC 1 _6alkyloxy, C 1 _6alkyloxyC 1 _6alkyloxy, aminoCl_6alkyloxy, mono- or di(C1_6alkyl)aminoCl_6alkyloxy, Arl, Ar2C1_6alkyl, Ar2oxy, Ar2C1_6alkyloxy, hydroxycarbonyl, C1_6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2_6alkenyl, 4,4-dimethyloxazolyl; or when on adjacent positions R2 and R3 taken together may form a bivalent radical of formula l0 -O-CH2-O- (a-1 ), -O-CH2-CH2-O- (a-2), -O-CH=CH- (a-3), -O-CH2-CH2- (a-4), -O-CH2-CH2-CH2- (a-5), or -CH=CH-CH=CH- (a-6);
R4 and RS each independently are hydrogen, halo, Arl, C1_6alkyl, hydroxyCl-6alkyl, C1_6alkyloxyCl_6alkyl , C1_6alkyloxy, C1_6alkylthio, amino, hydroxycarbonyl, C1_6alkyloxycarbonyl, C1_6alkylS(O)C1_6alkyl or C1_6alkylS(O)2C1_6alkyl;
R6 and R~ each independently are hydrogen, halo, cyano, C1_6alkyl, C1_6alkyloxy, 2o Ar2oxy, trihalomethyl, C1_6alkylthio, di(C1_6alkyl)amino, or when on adjacent positions R6 and R~ taken together may form a bivalent radical of formula -O-CH2-O- (c-1), or -CH=CH-CH=CH- (c-2);
R8 is hydrogen, C1_6alkyl, cyano, hydroxycarbonyl, C1_6alkyloxycarbonyl, C1_6alkyl-carbonylCl_6alkyl, cyanoCl_6alkyl, C1_6alkyloxycarbonylCl_6alkyl, carboxy-C1_6alkyl, hydroxyCl_6alkyl, aminoCl_6alkyl, mono- or di(C1_6alkyl)amino-C1_6alkyl, imidazolyl, haloCl_6alkyl, C1_6alkyloxyCl_6alkyl, aminocarbonyl-C1_6alkyl, or a radical of formula -O-R 10 (b-1 ), -S-R10 (b-2), -N-R11R12 (b-3), wherein RlOis hydrogen, C1_6alkyl, C1_6alkylcarbonyl, Arl, Ar2C1_6alkyl, C1_6alkyloxycarbonylCl_6alkyl, or a radical or formula -Alk2-OR13 or -Alk2-NR 14R 15 ;
R 11 is hydrogen, C 1 _ l2alkyl, Ar 1 or Ar2C 1 _6alkyl;
Rl2is hydrogen, C1_6alkyl, C1_l6alkylcarbonyl, C1_6alkyloxycarbonyl, C1_6alkylaminocarbonyl, Arl, Ar2C1_6alkyl, C1_6alkylcarbonyl-Cl_6alkyl, a natural amino acid, Arlcarbonyl, Ar2C1_6alkylcarbonyl, aminocarbonylcarbonyl, Cl_6alkyloxyCl_6alkylcarbonyl, hydroxy, C1_6alkyloxy, aminocarbonyl, di(CI_6alkyl)aminoCl_6alkylcarbonyl, amino, C1_6alkylamino, CI_6alkylcarbonylamino, or a radical or formula -Alk2-OR13 or -Alk2-NR14R15;
wherein Alk2 is C1_6alkanediyl;
RI3 is hydrogen, C1_6alkyl, Cl_6alkylcarbonyl, hydroxy-Cl_6alkyl, ArI or Ar2C1_6alkyl;
RI4 is hydrogen, Cl_6alkyl, ArI or Ar2Cl_6alkyl;
to RIS is hydrogen, CI_6alkyl, C1_6alkylcarbonyl, ArI or Ar2C 1 _6alkyl;
R 1 ~ is hydrogen, halo, cyano, C 1 _6alkyl, C 1 _6alkyloxycarbonyl, Arl ;
RIBis hydrogen, Cl_6alkyl, C1_6alkyloxy or halo;
R I9 is hydrogen or C I _6alkyl;
15 ArI is phenyl or phenyl substituted with CI_(alkyl, hydroxy, amino, CI_6alkyloxy or halo; and Ar2 is phenyl or phenyl substituted with C1_6alkyl, hydroxy, amino, Cl_6alkyloxy or halo.
2o The above described combinations are hereinafter referred to as combinations according to the invention. These combinations may provide a synergistic effect whereby they demonstrate an advantageous therapeutic effect which is greater than that which would have been expected from the effects of the individual components of the combinations.
In Formulas (I), (II) and (III), R4 or RS may also be bound to one of the nitrogen atoms in the imidazole ring. In that case the hydrogen on the nitrogen is replaced by R4 or RS
and the meaning of R4 and RS when bound to the nitrogen is limited to hydrogen, ArI, CI_6alkyl, hydroxyCl_6alkyl, CI_6alkyloxyCl_6alkyl, C1_6alkyloxycarbonyl, 3o Cl_6alkylS(O)CI_6alkyl, CI_6alkylS(O)ZC1_6alkyl.
Preferably the substituent RI8 is situated on the 5 or 7 position of the quinolinone moiety and substituent RI9 is situated on the 8 position when RI8 is on the 7-position.
Interesting compounds are these compounds of formula (I) wherein X is oxygen.
Also interesting compounds are these compounds of formula (I) wherein the dotted line represents a bond, so as to form a double bond.
Another group of interesting compounds are those compounds of formula (I) wherein RI is hydrogen, C1_6alkyl, C1_6alkyloxyCl_6alkyl, di(CI-6alkyl)aminoCl_6alkyl, or a radical of formula -Alkl-C(=O)-R9, wherein AIkI is methylene and R9 is Cl_galkyl-amino substituted with C1_6alkyloxycarbonyl.
Still another group of interesting compounds are those compounds of formula (I) wherein R3 is hydrogen or halo; and R2 is halo, C1_6alkyl, C2_6alkenyl, C1_6alkyloxy, to trihalomethoxy or hydroxyCl_6alkyloxy.
A further group of interesting compounds are those compounds of formula (I) wherein R2 and R3 are on adjacent positions and taken together to form a bivalent radical of formula (a-1), (a-2) or (a-3).
is A still further group of interesting compounds are those compounds of formula (I) wherein RS is hydrogen and R4 is hydrogen or CI_6alkyl.
Yet another group of interesting compounds are those compounds of formula (I) 2o wherein R~ is hydrogen; and R6 is C1_6alkyl or halo, preferably chloro, especially 4-chloro.
A particular group of compounds are those compounds of formula (I) wherein R8 is hydrogen, hydroxy, haloC I _6alkyl, hydroxyC I _6alkyl, cyanoC I _6alkyl, C 1 _6alkyloxy-25 carbonylCl_6alkyl, imidazolyl, or a radical of formula -NR1IR12 wherein R1I
is hydrogen or C1_l2alkyl and RI2 is hydrogen, CI_6alkyl, C1_6alkyloxy, hydroxy, C1_6alkyloxyCl_6alkylcarbonyl, or a radical of formula -Alk2-ORI3 wherein R13 is hydrogen or C I _6alkyl.
3o Preferred compounds are those compounds wherein RI is hydrogen, C1_6alkyl, CI_6alkyloxyCl_6alkyl, di(C1_6alkyl)aminoCl_6alkyl, or a radical of formula -AIkI-C(=O)-R9, wherein AIkI is methylene and R9 is Cl_galkylamino substituted with C1_6alkyloxycarbonyl; R2 is halo, C1_6alkyl, C2_6alkenyl, CI_6alkyloxy, trihalo-methoxy, hydroxyCl-6alkyloxy or ArI; R3 is hydrogen; R4 is methyl bound to the 35 nitrogen in 3-position of the imidazole; RS is hydrogen; R6 is chloro; R~
is hydrogen;
R$ is hydrogen, hydroxy, haloCl_6alkyl, hydroxyCl_6alkyl, cyanoCl-6alkyl, Cl_6alkyloxycarbonylCl_6alkyl, imidazolyl, or a radical of formula -NRI 1812 wherein R11 is hydrogen or C1-l2alkyl and R12 is hydrogen, C1-6alkyl, C1-(alkyloxy, C1_6alkyloxyCl_6alkylcarbonyl, or a radical of formula -Alk2-OR13 wherein R13 is C1-(alkyl; R17 is hydrogen and R18 is hydrogen.
Most preferred compounds are 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxyl1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2( 1H)-quinolinone, 6-[amino(4-chlorophenyl)-1-methyl-1H-imidazol-5-ylmethyl]-4-(3-chlorophenyl)-1-methyl-2( 1 H)-quinolinone;
6-[(4-chlorophenyl)hydroxyl1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-1-methyl-2( 1 H)-quinolinone;
6-[(4-chlorophenyl)( 1-methyl-1 H-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-1-methyl-2(1H)-quinolinone monohydrochloride.monohydrate;
6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-1-methyl-2( 1 H)-quinolinone, 6-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-4-(3-propyl-phenyl)-2(1H)-quinolinone; a stereoisomeric form thereof or a pharmaceutically acceptable acid or base addition salt; and (+)-6-[amino(4-chlorophenyl)( 1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (Compound 75 in Table 1 of the Experimental part of WO-97/21701) ; or a pharmaceutically acceptable acid addition salt thereof.
The latter compound is especially preferred.
Further preferred embodiments of the present invention include compounds of formula (IX) wherein one or more of the following restrictions apply:
~ =X'-XZ-X3 is a trivalent radical of formula (x-1), (x-2), (x-3), (x-4) or (x-9) wherein each R6 independently is hydrogen, C1_4alkyl, C1_4alkyloxycarbonyl, amino or aryl and R' is hydrogen;
~ >Y1-Y2- is a trivalent radical of formula (y-1), (y-2), (y-3), or (y-4) wherein each R9 3o independently is hydrogen, halo, carboxyl, Cl~,alkyl or C1_4alkyloxycarbonyl;
~ r is 0, 1 or 2;
~ s is 0 or 1;
~ tis0;
~ R' is halo, C1_6alkyl or two R1 substituents ortho to one another on the phenyl ring may independently form together a bivalent radical of formula (a-1);
~ RZ is halo;
~ R3 is halo or a radical of formula (b-1) or (b-3) wherein R1° is hydrogen or a radical of formula -Alk-OR13.

R" is hydrogen;
R'Z is hydrogen, C1_6alkyl, C1_6alkylcarbonyl, hydroxy, C~_6alkyloxy or mono-or di (C 1 _6alkyl)aminoC 1 _6alkylcarbonyl;
Alk is C1_6alkanediyl and R'3 is hydrogen;
R4 is a radical of formula (c-1) or (c-2) wherein R'6 is hydrogen, halo or mono- or di(C,_4alkyl)amino;
R" is hydrogen or C,_6alkyl;
~ aryl is phenyl.
1o A particular group of compounds consists of those compounds of formula (IX) wherein =X'-X2-X3 is a trivalent radical of formula (x-1), (x-2), (x-3), (x-4) or (x-9), >Y1-Y2 is a trivalent radical of formula (y-2), (y-3) or (y-4), r is 0 or 1, s is 1, t is 0, R' is halo, C~1_4~alkyl or forms a bivalent radical of formula (a-1), Rz is halo or Cl~alkyl, R~ is hydrogen or a radical of formula (b-1) or (b-3), R4 is a radical of formula (c-1) or (c-2), 15 R6 is hydrogen, Cl~alkyl or phenyl, R7 is hydrogen, R9 is hydrogen or C,~alkyl, R'° is hydrogen or -Alk-OR'3, R" is hydrogen and R'2 is hydrogen or C~_6alkylcarbonyl and R'3 is hydrogen;
Preferred compounds are those compounds of formula (IX) wherein =X'-XZ-X3 is a 2o trivalent radical of formula (x-1) or (x-4), >Yl-Y2 is a trivalent radical of formula (y-4), r is 0 or 1, s is 1, t is 0, R' is halo, preferably chloro and most preferably 3-chloro, Rz is halo, preferably 4-chloro or 4-fluoro, R31S hydrogen or a radical of formula (b-1) or (b-3), R4 is a radical of formula (c-1) or (c-2), R6 is hydrogen, R' is hydrogen, R9 is hydrogen, R'° is hydrogen, R" is hydrogen and R'2 is hydrogen;
Other preferred compounds are those compounds of formula (IX) wherein =X'-XZ-is a trivalent radical of formula (x-2), (x-3) or (x-4), >Y1-Y2 is a trivalent radical of formula (y-2), (y-3) or (y-4), r and s are 1, t is 0, R' is halo, preferably chloro, and most preferably 3-chloro or R' is CI_4alkyl, preferably 3-methyl, RZ is halo, preferably 3o chloro, and most preferably 4-chloro, R3 is a radical of formula (b-1) or (b-3), R4 is a radical of formula (c-2), R6 is Cl~alkyl, R9 is hydrogen, R'° and R"
are hydrogen and R'2 is hydrogen or hydroxy.
The most preferred compounds of formula (IX) are 7-[(4-fluorophenyl)(1H-imidazol-1-yl)methyl]-5-phenylimidazo[1,2-a]quinoline;
a-(4-chlorophenyl)-a-(1-methyl-1H-imidazol-5-yl)-5-phenylimidazo[ 1,2-a]quinoline-7-methanol;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-( 1-methyl-1 H-imidazol-5-yl)-imidazo-[ 1,2-a]quinoline-7-methanol;
S-(3-chlorophenyl)-a-(4-chlorophenyl)-a-( 1-methyl-1 H-imidazol-5-yl)imidazo-[ 1,2-a]quinoline-7-methanamine;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]quinoline-7-methanamine;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-1-methyl-a-( 1-methyl-1 H-imidazol-5-yl )-1,2,4-triazolo[4,3-a]quinoline-7-methanol;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-( 1-methyl-1 H-imidazol-5-yl)tetrazolo-[ 1,5-a]quinoline-7-methanamine;
to 5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-(1-methyl-1H-imidazol-5-yl)tetrazolo-[ 1,5-a]quinazoline-7-methanol;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-4,5-dihydro-a-( 1-methyl-1 H-imidazol-S-yl)tetrazolo[1,5-a]quinazoline-7-methanol;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]quinazoline-7-methanamine;
5-(3-chlorophenyl)-a-(4-chlorophenyl)-N-hydroxy-a-( 1-methyl-1 H-imi dazol-5-yl)-tetrahydro[ 1,5-a]quinoline-7-methanamine;
a-(4-chlorophenyl)-a-( 1-methyl-1H-imidazol-5-yl)-5-(3-methylphenyl)tetrazolo-[1,5-a]quinoline-7-methanamine; the pharmaceutically acceptable acid addition salts 2o and the stereochemically isomeric forms thereof.
5-(3-chlorophenyl)-a-(4-chlorophenyl)-a-( 1-methyl-1 H-imidazol-5-yl)tetrazolo-[1,5-a]quinazoline-7-methanamine, especially the (-) enantiomer, and its pharmaceutically acceptable acid addition salts are especially preferred.
As used in the foregoing definitions and hereinafter halo defines fluoro, chloro, bromo and iodo; C1_6alkyl defines straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl and the like; C1_galkyl encompasses the straight and branched 3o chained saturated hydrocarbon radicals as defined in C1_6alkyl as well as the higher homologues thereof containing 7 or 8 carbon atoms such as, for example heptyl or octyl; C1-l2alkyl again encompasses C1_galkyl and the higher homologues thereof containing 9 to 12 carbon atoms, such as, for example, nonyl, decyl, undecyl, dodecyl;
C1-l6alkyl again encompasses C1-l2alkyl and the higher homologues thereof containing 13 to 16 carbon atoms, such as, for example, tridecyl, tetradecyl, pentedecyl and hexadecyl; C2_6alkenyl defines straight and branched chain hydrocarbon radicals containing one double bond and having from 2 to 6 carbon atoms such as, for example, ethenyl, 2-propenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, and the WO 01/64197 PCT/EPOi/02166 like; Cl-6alkanediyl defines bivalent straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms, such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl and the branched isomers thereof. The term "C(=O)" refers to a carbonyl group, "S(0)" refers to a sulfoxide and "S(0)2" to a sulfon. The term "natural amino acid" refers to a natural amino acid that is bound via a covalent amide linkage formed by loss of a molecule of water between the carboxyl group of the amino acid and the amino group of the remainder of the molecule. Examples of natural amino acids are glycine, alanine, valine, leucine, isoleucine, methionine, proline, to phenylanaline, tryptophan, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine.
The pharmaceutically acceptable acid or base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and non-toxic base 15 addition salt forms which the compounds of formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) are able to form. The compounds of formulas (I), (II), (III), (N), (V), (VI), (VII), (VIII) or (IX) which have basic properties can be converted in their pharmaceutically acceptable acid addition salts by treating said base form with an appropriate acid. Appropriate acids comprise, for example, inorganic acids such as 2o hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric;
phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (i.e. butanedioic acid), malefic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
The compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) which have acidic properties may be converted in their pharmaceutically acceptable base addition salts by treating said acid form with a suitable organic or inorganic base.
Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and 3o earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
The terms acid or base addition salt also comprise the hydrates and the solvent addition forms which the compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

The term stereochemically isomeric forms of compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) may possess.
Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound.
All stereochemically isomeric forms of the compounds of formulae (I), (11), (III), (IV), (V), (VI), (VII), (VIII) or (IX) both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.
Some of the compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX) may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.
Whenever used hereinafter, the term "compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX)" is meant to include also the pharmaceutically acceptable acid or base addition salts and all stereoisomeric forms.
Preferred anti-tumor anthracycline derivatives for use in accordance with the invention include daunorubicin, doxorubicin and idarubicin referred to above.
Daunorubicin is commercially available for example as the hydrochloride salt from Bedford Laboratories under the trade name Cerubidine, and may be prepared for example as described in patent specification No. 4020270, or by processes analogous thereto.
Doxorubicin is commercially available for example as the hydrochloride salt from Astra, and may be prepared for example as described in U.S. patent specification No.
3803124 or by processes analogous thereto. Idarubicin is commercially available for example as the hydrochloride salt from Pharmacia & Upjohn under the trade name Idamycin, and may be prepared for example as described in U.S. patent specification No. 4046878 or by processes analogous thereto Other anti-tumor anthracycline derivatives may be prepared in conventional manner for example by processes analogous to those described above for daunorubicin, doxorubicin and idarubicin.

The present invention also relates to combinations according to the invention for use in medical therapy for example for inhibiting the growth of tumor cells.
The present invention also relates to the use of combinations according to the invention for the preparation of a pharmaceutical composition for inhibiting the growth of tumor cells.
The present invention also relates to a method of inhibiting the growth of tumor cells in a human subject which comprises administering to the subject an effective amount of a combination according to the invention.
This invention further provides a method for inhibiting the abnormal growth of cells, including transformed cells, by administering an effective amount of a combination according to the invention. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g. loss of contact inhibition). This includes the abnormal growth of : (1) tumor cells (tumors) expressing an activated ras oncogene;
(2) tumor cells in which the ras protein is activated as a result of oncogenic mutation of another gene; (3) benign and malignant cells of other proliferative diseases in which aberrant ras activation occurs. Furthermore, it has been suggested in literature that ras oncogenes not only contribute to the growth of of tumors in vivo by a direct effect on tumor cell growth but also indirectly, i.e. by facilitating tumor-induced angiogenesis (Rak. J. et al, Cancer Research, S5, 4575-4580, 1995). Hence, pharmacologically targetting mutant ras oncogenes could conceivably suppress solid tumor growth in vivo, in part, by inhibiting tumor-induced angiogenesis.
This invention also provides a method for inhibiting tumor growth by administering an effective amount of a combination according to the present invention, to a subject, e.g.
a mammal (and more particularly a human) in need of such treatment. In particular, this invention provides a method for inhibiting the growth of tumors expressing an activated ras oncogene by the administration of an effective amount of combination according to the present invention. Examples of tumors which may be inhibited include, but are not limited to, lung cancer (e.g. adenocarcinoma and including non-small celll lung cancer), pancreatic cancers (e.g. pancreatic carcinoma such as, for example exocrine pancreatic carcinoma), colon cancers (e.g. colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), hematopoietic tumors of lymphoid lineage (e.g. acute lymphocytic leukemia, B-cell lymphoma, Burkitt's lymphoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), tumors of mesenchymal origin (e.g. fibrosarcomas and rhabdomyosarcomas), melanomas, teratocarcinomas, neuroblastomas, gliomas, benign tumor of the skin (e.g.
keratoacanthomas), breast carcinoma (e.g. advanced breast cancer), kidney carninoma, ovary carcinoma, bladder carcinoma and epidermal carcinoma.
This invention also provides a method for inhibiting proliferative diseases, both benign and malignant, wherein ras proteins are aberrantly activated as a result of oncogenic mutation in genes, i.e. the ras gene itself is not activated by mutation to an oncogenic mutation to an oncogenic form, with said inhibition being accomplished by the l0 administration of an effective amount of a combination according to the invention, to a subject in need of such a treatment. For example, the benign proliferative disorder neurofibromatosis, or tumors in which ras is activated due to mutation or overexpression of tyrosine kinase oncogenes may be inhibited by the combinations according to the invention.
The anti-tumor anthracycline derivative and the farnesyl transferase inhibitor may be administered simultaneously (e.g. in separate or unitary compositions) or sequentially in either order. In the latter case, the two compounds will be administered within a period and in an amount and manner that is sufficient to ensure that an advantageous or synergistic effect is achieved. It will be appreciated that the preferred method and order of administration and the respective dosage amounts and regimes for each component of the combination will depend on the particular anti-tumor anthracycline derivative and farnesyl transferase inhibitor being administered, their route of administration, the particular tumor being treated and the particular host being treated. The optimum method and order of administration and the dosage amounts and regime can be readily determined by those skilled in the art using conventional methods and in view of the information set out herein.
The farnesyl transferase inhibitor is advantageously administered in an effective 3o amount of from 0.0001 mg/kg to 100 mg/kg body weight, and in particular from 0.001 mg/kg to 10 mg/kg body weight. More particularly, for an adult patient, the dosage is conveniently in the range of 50 to SOOmg bid, advantageously 100 to 400 mg bid and particularly 300mg bid.
The anti-tumor anthracycline derivative is advantageously administered in a dosage of 10 to 75 mg per square meter (mg/m2) of body surface area, for example 15 to mg/m2, particularly for doxorubicin in a dosage of about 40 to 75 mg/mz, for daunorubicin in a dosage of about 25 to 45mg/m2 , and for idarubicin in a dosage of about 10 to 15 mg/m2 per course of treatment. These dosages may be administered for example once, twice or more per course of treatment, which may be repeated for example every 7,14,21 or 28 days.
It is especially preferred to administer the farnesyl tranferase inhibitor at a dosage of 100 or 200mg bid for 7, 14, 21 or 28 days with a dosage of the anti-tumor anthracycline derivative in the ranges indicated above.
In view of their useful pharmacological properties, the components of the combinations to according to the invention, i.e. the anti-tumor anthracycline derivative and the farnesyl transferase inhibitor may be formulated into various pharmaceutical forms for administration purposes. The components may formulated separately in individual pharmaceutical compositions or in a unitary pharmaceutical composition containing both components. Farnesyl protein transferase inhibitors can be prepared and 15 formulated into pharmaceutical compositions by methods known in the art and in particular according to the methods described in the published patent specifications mentioned herein and incorporated by reference; for the compounds of formulae (I), (II) and (III) suitable examples can be found in WO-97/21701. Compounds of formulae (IV), (V), and (VI) can be prepared and formulated using methods described in WO
20 97/16443, compounds of formulae (VII) and (VIII) according to methods described in WO 98/40383 and WO 98/49157 and compounds of formula (IX) according to methods described in WO 00/39082 respectively.
The present invention therefore also relates to a pharmaceutical composition 25 comprising an anti-tumor anthracycline derivative and a farnesyl tranferase inhibitor of formula (I) together with one or more pharmaceutical Garners. To prepare pharmaceutical compositions for use in accordance with the invention, an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable 3o carrier, which Garner may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, 35 for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical Garners are obviously employed. For parenteral compositions, the Garner will usually comprise sterile water, at least in large part, though other ingredients, to aid solubility for example, may be included.
Injectable solutions, for example, may be prepared in which the Garner comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a to suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage.
Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical Garner. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
It may be appropriate to administer the required dose of each component of the combination as two, three, four or more sub-doses at appropriate intervals throughout the course of treatment Said sub-doses may be formulated as unit dosage forms, for example, in each case containing independently 0.01 to 500 mg, for example 0.1 to 200 mg and in particular 1 to 100mg of each active ingredient per unit dosage form.
Experimental Testing of Combinations for Inhibition of Tumor Growth The combinations according to the invention may be tested for their efficacy in inhibiting tumor growth using conventional assays described in the literature for example the HTB 177 lung carcinoma described by Liu M et al, Cancer Research, Vol.
58, No.2l, 1 November 1998, pages 4947-4956, and the anti-mitotic assay described by Moasser M et al, Proc. Natl. Acad. Sci. USA, Vol. 95, pages 1369-1374, February 1998. Other in vitro and in vivo models for determining ant-tumor effects of combinations and possible synergy of the combinations according to the invention are described in WO 98/54966 and WO 98/32114. Clinical models for determining the efficacy and possible synergism for combination therapy in the clinic are generally described in Cancer: Principles and Practice of Oncology, Fifth Edition, edited by Vincent T DeVita, Jr., Samuel Hellman, Steven A. Rosenberg, Lippincott-Raven, Philadelphia, 1997, especially Chapter 17, pages 342-346.

Claims (14)

Claims
1. A combination of an anti-tumor anthracyline derivative and a farnesyl transferase inhibitor selected from compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) and (IX) below:

the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond;
X is oxygen or sulfur;
R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C 1-6alkyl)aminoC1-6(alkyl, aminoC1-6alkyl, or a radical of formula -AIk1-C(=O)-R9, -AIk1-S(O)-R9 or -AIkI-S(O)2-R9, wherein AIk1 is C1-6alkanediyl, R9 is hydroxy, C1-6alkyl, C1-6alkyloxy, amino, C1-6alkylamino or C1-6alkylamino substituted with C1-6alkyloxycarbonyl;
R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, 4,4-dimethyloxazolyl; or when on adjacent positions R2 and R3 taken together may form a bivalent radical of formula -O-CH2-O- (a-1), -O-CH2-CH2-O- (a-2), -O-CH=CH- (a-3), -O-CH2-CH2- (a-4), -O-CH2-CH2-CH2- (a-5), or -CH=CH-CH=CH- (a-6);
R4 and R5 each independently are hydrogen, halo, Arl, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;
R6 and R7 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxy, Ar2oxy, tr-ihalomethyl, C1-6alkylthio, di(C1-6alkyl)amino, or when on adjacent positions R6 and R7 taken together may form a bivalent radical of formula -O-CH2-O- (c-1), or -CH=CH-CH=CH- (c-2);
R8 is hydrogen, C1-6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonylC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, carboxyC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)-aminoC1-6alkyl, imidazolyl, haloC1-6alkyl, C1-6alkyloxyC1-6alkyl, aminocarbonylC1-6alkyl, or a radical of formula -O-R 10 (b-1), -S-R 10 (b-2), -N-R 11 R 12 (b-3), wherein R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Arl, Ar2C1-6alkyl, C1-6alkyloxycarbonylC 1-6alkyl, or a radical or formula -Alk2-OR 13 or -Alk2-NR14R15;
R11 is hydrogen, C1-l2alkyl, Ar1 or Ar2C1-6alkyl;
R12 is hydrogen, C1-6alkyl, C1-l6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylaminocarbonyl, Arl, Ar2C1-6alkyl, C1-6alkylcarbonyl-C1-6alkyl, a natural amino acid, Arlcarbonyl, Ar2C1-6alkylcarbonyl, aminocarbonylcarbonyl, C1-6alkyloxyC1-6alkylcarbonyl, hydroxy, C1-6alkyloxy, aminocarbonyl, di(C1-6alkyl)aminoC1-6alkylcarbonyl, amino, C1-6alkylamino, C1-6alkylcarbonylamino, or a radical or formula -Alk2-OR13 or -Alk2-NR14R15;
wherein Alk2 is C1-6alkanediyl;
R13 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, hydroxyC1-6alkyl, Ar1 or Ar2C1-6alkyl;
R14 is hydrogen, C1-6alkyl, Ar1 or Ar2C1-6alkyl;
R15 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar1 or Ar2C1-6alkyl;
R17 is hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxycarbonyl, Ar1;
R18 is hydrogen, C1-6alkyl, C1-6alkyloxy or halo;
R19 is hydrogen or C1-6alkyl;
Ar1 is phenyl or phenyl substituted with C1-6alkyl, hydroxy, amino, C1-6alkyloxy or halo; and Ar2 is phenyl or phenyl substituted with C1-6alkyl, hydroxy, amino, C1-6alkyloxy or halo.

the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond;
X is oxygen or sulfur;
R1 is hydrogen, C1-l2alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridyl-C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula -Alk1-C(=O)-R9, -Alkl-S(O)-R9 or -Alkl-S(O)2-R9, wherein Alk1 is C1-(alkanediyl, R9 is hydroxy, C1-6alkyl, C1-6alkyloxy, amino, C1-8alkylamino or C1-6alkylamino substituted with C1-6alkyloxycarbonyl;
R2 and R3 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, amino-C1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Arl, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; or when on adjacent positions R2 and R3 taken together may form a bivalent radical of formula -O-CH2-O- (a-1 ), -O-CH2-CH2-O- (a-2), -O-CH=CH- (a-3), -O-CH2-CH2- (a-4), -O-CH2-CH2-CH2- (a-5), or -CH=CH-CH=CH- (a-6);
R4 and R5 each independently are hydrogen, Ar1, C1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;
R6 and R7 each independently are hydrogen, halo, cyano, C1-6alky1, C1-6alkyloxy or Ar2oxy;
R8 is hydrogen, C1-6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkyl-carbonylC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, hydroxy-carbonylC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)-aminoC1-6alkyl, haloC1-(alkyl, C1-6alkyloxyC1-6alkyl, aminocarbonylC1-6alkyl, Ar1, Ar2C1-6alkyloxyC1-6alkyl, C1-6alkylthioC 1-6alkyl;
R10 is hydrogen, C 1-6alkyl, C 1-6alkyloxy or halo;
R11 is hydrogen or C1-6alkyl;
Ar1 is phenyl or phenyl substituted with C1-6alkyl,hydroxy,amino,C1-6alkyloxy or halo;
Ar2 is phenyl or phenyl substituted with C1-6alkyl, hydroxy, amino, C1-6alkyloxy or halo.

the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond;
X is oxygen or sulfur;
-A- is a bivalent radical of formula -CH=CH- (a-1), -CH2-S- (a-6), -CH2-CH2- (a-2), -CH2-CH2-S- (a-7), -CH2-CH2-CH2- (a-3), -CH=N- (a-8), -CH2-O- (a-4), -N=N- (a-9), or -CH2-CH2-O- (a-5), -CO-NH- (a-10);
wherein optionally one hydrogen atom may be replaced by C1-4alkyl or Ar1;
R1 and R2 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-(alkyloxy, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar2, Ar2-C1-(alkyl, Ar2-oxy, Ar2-C1-6alkyloxy; or when on adjacent positions R1 and R2 taken together may form a bivalent radical of formula -O-CH2-O- (b-1 ), -O-CH2-CH2-O- (b-2), -O-CH=CH- (b-3), -O-CH2-CH2- (b-4), -O-CH2-CH2-CH2- (b-5), or -CH=CH-CH=CH- (b-6);
R3 and R4 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxy, Ar3-oxy, C1-6alkylthio, di(C1-6alkyl)amino, trihalomethyl, trihalomethoxy, or when on adjacent positions R3 and R4 taken together may form a bivalent radical of formula -O-CH2-O- (c-1), -O-CH2-CH2-O- (c-2), or -CH=CH-CH=CH- (c-3);
R5 is a radical of formula wherein R13 is hydrogen, halo, Ar4, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxy-C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;
R14 is hydrogen, C1-6alkyl or di(C1-4alkyl)aminosulfonyl;
R6 is hydrogen, hydroxy, halo, C1-6alkyl, cyano, haloC1-6alkyl, hydroxyC1-6alkyl, cyanoC1-6alkyl, aminoC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl, aminocarbonylC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, C1-6alkylcarbonyl-C1-6alkyl, C1-6alkyloxycarbonyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, Ar5, Ar5-C1-6alkyloxyC1-6alkyl; or a radical of formula -O-R7 (e-1), -S-R7 (e-2), -N-R8R9 (e-3), wherein R7 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar6, Ar6-C1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, or a radical of formula -Alk-OR10 or -Alk-NR11R12;
R8 is hydrogen, C1-6alkyl, Ark or Ark-C1-6alkyl;
R9 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylaminocarbonyl, Ar8 Ar8-C1-6alkyl, C1-6alkylcarbonyl-C1-6alkyl, Ar8-carbonyl, Ar8-C1-6alkylcarbonyl, aminocarbonyl-carbonyl, C1-6alkyloxyC1-6alkylcarbonyl, hydroxy, C1-6alkyloxy, aminocarbonyl, di(C1-6alkyl)aminoC1-6alkylcarbonyl, amino, C1-6alkylamino, C1-6alkylcarbonylamino, or a radical or formula -Alk-OR10 or -Alk-NR11R12;
wherein Alk is C1-6alkanediyl;
R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, hydroxyC1-6alkyl, Ar9 or Ar9-C1-6alkyl;
R11 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar10 or Ar10-C1-6alkyl;
R12 is hydrogen, C1-6alkyl, Ar11 or Ar11-C1-6alkyl; and Ar1 to Ar11 are each independently selected from phenyl; or phenyl substituted with halo, C1-6alkyl, C1-6alkyloxy or trifluoromethyl.

the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond;
X is oxygen or sulfur;
R1 and R2 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar1C1-6alkyl, Ar1oxy or Ar1C1-6alkyloxy;
R3 and R4 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxy, Ar1oxy, C1-6alkylthio, di(C1-6alkyl)amino, trihalomethyl or trihalomethoxy;
R5 is hydrogen, halo, C1-6alkyl, cyano, haloC1-6alkyl, hydroxyC1-6alkyl, cyanoC1-6alkyl, aminoC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl, aminocarbonylC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, C1-6alkylcarbonyl-C1-6alkyl, C1-6alkyloxycarbonyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, Ar1, Ar1C1-6alkyloxyC1-6alkyl; or a radical of formula -O-R10 (a-1), -S-R10 (a-2), -N-R11R12 (a-3), wherein R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar1, Ar1C1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, or a radical of formula -Alk-OR13 or -Alk-NR14R15;
R11 is hydrogen, C1-6alkyl, Ar1 or Ar1 C1-6alkyl;
R12 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylaminocarbonyl, Ar1, Ar1C1-6alkyl, C1-6alkylcarbonyl-C1-6alkyl, Ar1carbonyl, Ar1C1-6alkylcarbonyl, aminocarbonyl-carbonyl, C1-6alkyloxyC1-6alkylcarbonyl, hydroxy, C1-6alkyloxy, aminocarbonyl, di(C1-6alkyl)aminoC1-6alkylcarbonyl, amino, C1-6alkylamino, C1-6alkylcarbonylamino, or a radical or formula -Alk-OR13 or -Alk-NR14R15;

wherein Alk is C1-6alkanediyl;
R13 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, hydroxy-C1-6alkyl, Ar1 or Ar1C1-6alkyl;
R14 is hydrogen, C1-6alkyl, Ar1 or Ar1C1-6alkyl;
R15 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, Ar1 or Ar1 C1-6alkyl;
R6 is a radical of formula wherein R16 is hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, C1-6alkyloxycarbonyl, C1-6alkylthioC1-6alkyl, C1-6alkylS(O)C1-6alkyl or C1-6alkyl-S(O)2C1-6alkyl;
R17 is hydrogen, C1-6alkyl or di(C1-4alkyl)aminosulfonyl;
R7 is hydrogen or C1-6alkyl provided that the dotted line does not represent a bond;
R8 is hydrogen, C1-6alkyl or Ar2CH2 or Het1CH2;
R9 is hydrogen, C1-6alkyl , C1-6alkyloxy or halo; or R8 and R9 taken together to form a bivalent radical of formula -CH=CH- (c-1), -CH2-CH2- (c-2), -CH2-CH2-CH2- (c-3), -CH2-O- (c-4), or -CH2-CH2-O- (c-5);

Ar1 is phenyl; or phenyl substituted with 1 or 2 substituents each independently selected from halo, C1-6alkyl, C1-6alkyloxy or trifluoromethyl;
Ar2 is phenyl; or phenyl substituted with 1 or 2 substituents each independently selected from halo, C1-6alkyl, C1-6alkyloxy or trifluoromethyl; and Het1 is pyridinyl; pyridinyl substituted with 1 or 2 substituents each independently selected from halo, C1-6alkyl, C1-6alkyloxy or trifluoromethyl and or the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein =X1-X2-X3- is a trivalent radical of formula =N-CR6=CR7- (x-1), =CR6-CR7=CR8- (x-6), =N-N=CR6- (x-2), =CR6-N=CR7- (x-7), =N-NH-C(=O)- (x-3), =CR6-NH-C(=O)- (x-8), or =N-N=N- (x-4), =CR6-N=N- (x-9);
=N-CR6=N- (x-5), wherein each R6, R7 and R8 are independently hydrogen, C1-4alkyl, hydroxy, C1-4alkyloxy, aryloxy, C1-4alkyloxycarbonyl, hydroxyC1-4alkyl, C1-4alkyloxyC1-4alkyl, mono- or di(C1-4alkyl)aminoC1-4alkyl, cyano, amino, thio, C1-4alkylthio, arylthio or aryl;

>Y1-Y2- is a trivalent radical of formula >CH-CHR9- (y-1), >C=N- (y-2), >CH-NR9- (y-3),or >C=CR9- (y-4);

wherein each R9 independently is hydrogen, halo, halocarbonyl, aminocarbonyl, hydroxyC1-4alkyl, cyano, carboxyl, C1-4alkyl, C1-4alkyloxy, C1-4alkyloxyC1-4alkyl, C1-4alkyloxycarbonyl, mono- or di(C1-4alkyl)amino, mono- or di(C1-4alkyl)aminoC1-4alkyl, aryl;
r and s are each independently 0, 1, 2, 3, 4 or 5;
t is 0, 1, 2 or 3;
each R1 and R2 are independently hydroxy, halo, cyano, C1-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkylthio, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)amino, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, aryl, arylC1-6alkyl, aryloxy or arylC1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, aminocarbonyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)aminocarbonyl, mono- or di(C1-6alkyl)aminoC1-6alkyl; or two R1 or R2 substituents adjacent to one another on the phenyl ring may independently form together a bivalent radical of formula -O-CH2-O- (a-1), -O-CH2-CH2-O- (a-2), -O=CH=CH- (a-3), -O-CH2-CH2- (a-4), -O-CH2-CH2- CH2- (a-5), or -CH=CH-CH=CH- (a-6);

R3 is hydrogen, halo, C1-6alkyl, cyano, haloC1-6alkyl, hydroxyC1-6alkyl, cyanoC1-6alkyl, aminoC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl, aminocarbonylC1-6alkyl, hydroxycarbonyl, hydroxycarbonylC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, C1-6alkylcarbonylC1-6alkyl, C1-6alkyloxycarbonyl, aryl, arylC1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl;
or a radical of formula -O-R10 (b-1), -S-R10 (b-2), -NR11R12 (b-3), wherein R10 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, aryl, arylC1-6alkyl, C1-6alkyloxy-carbonylC1-6alkyl, or a radical of formula -Alk-OR13 or -Alk-NR14R15;
R11 is hydrogen, C1-6alkyl, aryl or arylC1-6alkyl;
R12 is hydrogen, C1-6alkyl, aryl, hydroxy, amino, C1-6alkyloxy, C1-6alkylcarbonyl-C1-6alkyl, arylC1-6alkyl, C1-6alkylcarbonylamino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonyl, aminocarbonyl, arylcarbonyl, haloC1-6alkylcarbonyl, arylC1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkyloxyC1-6alkylcarbonyl, mono- or di(C1-6alkyl)aminocarbonyl wherein the alkyl moiety may optionally be substituted by one or more substituents independently selected from aryl or C1-3alkyloxycarbonyl, aminocarbonylcarbonyl, mono- or di(C1-6alkyl)aminoC1-6alkylcarbonyl, or a radical or formula -Alk-OR13 or -Alk-NR14R15;
wherein Alk is C1-6alkanediyl;
R13 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, hydroxyC1-6alkyl, aryl or arylC1-6alkyl;
R14 is hydrogen, C1-6alkyl, aryl or arylC1-6alkyl;
R15 is hydrogen, C1-6alkyl, C1-6alkylcarbonyl, aryl or arylC1-6alkyl;
R4 is a radical of formula wherein R16 is hydrogen, halo, aryl, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, mono- or di(C1-4alkyl)amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylthioC1-6alkyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;
R16 may also be bound to one of the nitrogen atoms in the imidazole ring of formula (c-1) or (c-2), in which case the meaning of R16 when bound to the nitrogen is limited to hydrogen, aryl, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyl-oxyC1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl;
R17 is hydrogen, C1-6alkyl, C1-6alkyloxyC1-6alkyl, arylC1-6alkyl, trifluoromethyl or di(C1-4alkyl)aminosulfonyl;
R5 is C1-6alkyl , C1-6alkyloxy or halo;
aryl is phenyl, naphthalenyl or phenyl substituted with 1 or more substituents each independently selected from halo, C1-6alkyl, C1-6alkyloxy or trifluoromethyl.
2. A combination as claimed in claim 1 wherein the farnesyl protein transferase inhibitor is a compound of formula (I) wherein X is oxygen and the dotted line represents a bond.
3. A combination as claimed in claim 1 or claim 2 wherein the farnesyl protein transferase inhibitor is a compound of formula (I) wherein R1 is hydrogen, C1-6alkyl, C1-6alkyloxyC1-6alkyl or mono- or di(C1-6alkyl)aminoC1-6alkyl and wherein R3 is hydrogen and R2 is halo, C1-6alkyl, C2-6alkenyl, C1-6alkyloxy, trihalomethoxy or hydroxyC1-6alkyloxy.
4. A combination as claimed in any of the preceding claims wherein the farnesyl protein transferase inhibitor is a compound of formula (I) wherein R8 is hydrogen, hydroxy, haloC1-6alkyl, hydroxyC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, imidazolyl, or a radical of formula -NR11R12 wherein R11 is hydrogen or C1-12alkyl and R12 is hydrogen, C1-6alkyl, C1-6alkyloxy, C1-6alkyloxyC1-6alkylcarbonyl, hydroxy, or a radical of formula -Alk2-OR13 wherein R13 is hydrogen or C1-6alkyl.
5. A combination as claimed in claim 1 wherein the farnesyl transferase inhibitor is selected from:
4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)-methyl]-1-methyl-2(1H)-quinolinone, 6-[amino(4-chlorophenyl)-1-methyl-1H-imidazol-5-ylmethyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone;
6-[(4-chlorophenyl)hydroxyl1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethoxy-phenyl)-1-methyl-2(1H)-quinolinone;
6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-1-methyl-2(1H)-quinolinone monohydrochloride monohydrate;
6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethoxyphenyl)-1-methyl-2(1H)-quinolinone, and 6-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-4-(3-propylphenyl)-2(1H)-quinolinone; a stereoisomeric form thereof or a pharmaceutically acceptable acid or base addition salts thereof.
6. A combination as claimed in claim 1 wherein the farnesyl transferase inhibitor is (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chloro-phenyl)-1-methyl-2(1H)-quinolinone; or a pharmaceutically acceptable acid addition salt thereof.
7. A combination as claimed in claim 1 wherein the farnesyl protein transferase inhibitor is a compound of formula (IX) wherein =X1-X2-X3 is a trivalent radical of formula (x-2), (x-3) or (x-4), >Y1-Y2 is a trivalent radical of formula (y-2), (y-3) or (y-4), r and s are 1, t is 0, R1 is halo, preferably chloro, and most preferably 3-chloro or R1 is C1-4alkyl, preferably 3-methyl, R2 is halo, preferably chloro, and most preferably 4-chloro, R3 is a radical of formula (b-1) or (b-3), R4 is a radical of formula (c-2), R6 is C1-4alkyl, R9 is hydrogen, R10 and R11 are hydrogen and R12 is hydrogen or hydroxy.
8. A combination as claimed in claim 1 wherein the farnesyl protein transferase inhibitor is 5-(3-chlorophenyl)-.alpha.-(4-chlorophenyl)-.alpha.-(1-methyl-1H-imidazol-5-yl)tetrazolo[1,5-a]quinazoline-7-methanamine or a pharmaceutically acceptable acid addition salt thereof.
9. A combination as claimed in any of the preceding claims in which the anti-tumor anthracyline derivative is daunorubicin, doxorubicin or idarubicin.
10. A combination as claimed in any of the preceding claims in the form of a pharmaceutical composition comprising an anti-tumor anthracycline derivative and a farnesyl transferase inhibitor selected from compounds of formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII) and (IX) (as defined in claim 1) together with one or more pharmaceutical carriers.
11. A combination as claimed in any of the preceding claims for use in medical therapy.
12. A combination as claimed in claim 11 for inhibiting the growth of tumor cells.
13. Use of a combination as claimed in any of claims 1 to 12 in the manufacture of a pharmaceutical composition for inhibiting the growth of tumor cells.
14. A method of inhibiting the growth of tumor cells in a human subject which comprises administering to the subject an effective amount of a combination as claimed in any of claims 1 to 12.
CA002397253A 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives Abandoned CA2397253A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200696 2000-02-29
EP00200696.3 2000-02-29
PCT/EP2001/002166 WO2001064197A2 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives

Publications (1)

Publication Number Publication Date
CA2397253A1 true CA2397253A1 (en) 2001-09-07

Family

ID=8171115

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002397253A Abandoned CA2397253A1 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives

Country Status (5)

Country Link
EP (1) EP1267872A2 (en)
JP (1) JP2003525237A (en)
AU (1) AU2001244167A1 (en)
CA (1) CA2397253A1 (en)
WO (1) WO2001064197A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1542691B1 (en) * 2002-09-27 2009-01-07 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Composition for the treatment of nasopharyngeal carcinoma and use thereof
EP2284157A1 (en) 2003-12-12 2011-02-16 Wyeth Quinolines useful in treating cardiovascular disease
US20070213366A1 (en) 2005-12-23 2007-09-13 Justman Craig J Treatment of Synucleinopathies
ME02794B (en) 2012-10-16 2018-01-20 Janssen Pharmaceutica Nv METHYLENE-LINED CHINOLINYL MODULATORS OF ROR-GAMMA-T
JP6250686B2 (en) 2012-10-16 2017-12-20 ヤンセン ファーマシューティカ エヌ．ベー． Rorγt heteroaryl linked quinolinyl modulator
US9309222B2 (en) 2012-10-16 2016-04-12 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
ES2742843T3 (en) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv ROR quinolinyl modulators (gamma) t
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
ES2770727T3 (en) 2013-10-15 2020-07-02 Janssen Pharmaceutica Nv Alkyl-Linked Quinylonyl Modulators of ROR (gamma) t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
ATE321757T1 (en) * 1995-12-08 2006-04-15 Janssen Pharmaceutica Nv (IMIDAZOLE-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
KR100520401B1 (en) * 1997-04-25 2005-10-12 얀센 파마슈티카 엔.브이. Farnesyl transferase inhibiting quinazolinones
BR9814419A (en) * 1997-12-22 2000-10-10 Schering Corp "combination of benzocycloheptapyridine compounds and antineoplastic drugs for the treatment of proliferative diseases"
WO1999065494A1 (en) * 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CA2336054A1 (en) * 1998-07-02 2000-01-13 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
US6458800B1 (en) * 1998-12-23 2002-10-01 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives

Also Published As

Publication number Publication date
WO2001064197A2 (en) 2001-09-07
AU2001244167A1 (en) 2001-09-12
JP2003525237A (en) 2003-08-26
WO2001064197A3 (en) 2002-03-21
EP1267872A2 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
CA2397349A1 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
CA2397657A1 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
CA2397240A1 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
CA2396865C (en) Farnesyl protein transferase inhibitors for treating breast cancer
CA2397256A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
CA2397446A1 (en) Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
CA2397558A1 (en) Dosing regimen
CA2397690A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
CA2397694A1 (en) Farnesyl protein transferase inhibitor combinations
CA2397448A1 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
CA2397425A1 (en) Farnesyl protein transferase inhibitor combinations with taxane compounds
CA2397253A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
US20030050323A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
US20030060480A1 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
CA2397475A1 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
US20030125268A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives

Legal Events

Date Code Title Description
FZDE Dead